Clinical Research Directory
Browse clinical research sites, groups, and studies.
Proteinuria in Renal Transplant Patients Treated with Dapagliflozin
Sponsor: University Hospital, Montpellier
Summary
The prevalence of chronic kidney disease is rising steadily and represents a major public health challenge. Hypertension and proteinuria are two factors strongly associated with the progression of chronic kidney disease (CKD) and the high risk of cardiovascular complications. Achieving blood pressure control and reducing proteinuria is therefore a major objective in the management of chronic renal failure. Until recently, inhibitors of the renin-angiotensin-aldosterone system were the only therapeutic class known to have both anti-proteinuric and anti-hypertensive action, reducing the risk of progression to end-stage renal disease. The Investigators intend to conduct an observational study with the primary objective of studying the evolution of proteinuria in kidney transplant patients treated with dapagliflozin according to the marketing authorization. The secondary objectives of the study are to investigate other expected benefits, including effects on renal function and metabolic effects, as well as potential side-effects of this treatment in this population.
Official title: Evolution of Proteinuria in Renal Transplant Patients Treated with Dapagliflozin for Nephroprotection. DAPAGREFFE
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2024-01-04
Completion Date
2026-01-01
Last Updated
2025-03-06
Healthy Volunteers
No
Conditions
Interventions
Follow-up at D14
A blood test and urinary test will be performed at D14.
Follow-up at M1
A blood test and urinary test will be performed at M1.
Locations (1)
University Hospital of Montpellier
Montpellier, France